Search
CorMedix Inc
CRMDAdd to Watchlist
9.015USD
+0.345+3.98%
Market hours （ET）Quotes delayed by 15 min
706.73MMarket Cap
3.71P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of CorMedix Inc is 8.29, ranking 44 out of 157 in the Pharmaceuticals industry. The average price target is 20.00, with a high of 22.00 and a low of 14.00.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
15.200
Target Price
+75.32%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
175
Total
6
Median
8
Average
Company name
Ratings
Analysts
CorMedix Inc
CRMD
5
Biogen Inc
BIIB
38
Amgen Inc
AMGN
38
Eli Lilly and Co
LLY
35
AbbVie Inc
ABBV
34
Vertex Pharmaceuticals Inc
VRTX
34
1
2
3
...
35
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is CorMedix Inc's expected revenue for the next quarter?
CorMedix Inc's expected revenue is 95.62M.
What is CorMedix Inc's price target?
Analysts forecast that CorMedix Inc's price target is USD 20.00, with the highest forecast at USD 22.00 and the lowest forecast at USD 14.00.
How have CorMedix IncCRMD's recent earnings per share performed?
The market expectation was USD 0.49, while CorMedix IncCRMD's earnings per share (EPS) for the previous quarter was USD 0.18. EPS for the next quarter is expected at USD 0.24.
What is the analyst rating for CorMedix Inc?
Based on the ratings of CorMedix Inc's stock from 5 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
